Advertisement

Joint pain and falls among women with breast cancer on aromatase inhibitors

  • Coby Basal
  • Emily Vertosick
  • Theresa A. Gillis
  • Qing Li
  • Ting Bao
  • Andrew Vickers
  • Jun J. Mao
Original Article
  • 143 Downloads

Abstract

Purpose

Arthralgia is common among women with breast cancer on adjuvant aromatase inhibitor (AI) therapy. Pain is associated with falls in the general population; however, little is known about the relationship between arthralgia and falls among AI users. Our objective was to determine whether joint pain severity and interference predict future falls.

Methods

We conducted a prospective cohort study of postmenopausal women with stage I-III estrogen receptor-positive breast cancer who were prescribed a third-generation AI. Arthralgia symptoms were measured at baseline using a modified version of the Brief Pain Inventory. Fall occurrence was obtained at 24-month follow-up.

Results

Among 667 participants (median age 63 years, interquartile range 57–69 years), 232 (35%, 95% CI 31 to 39%) reported falls 12–24 months after baseline. Among women who fell, 65 (28%) reported seeking medical assistance. After controlling for multiple fall risk factors, we found significant non-linear associations between baseline joint pain severity and risk of falls (p = 0.001). Women with joint pain severity scores ≥ 4 had a more than twofold increase in fall risk compared to those without pain (41% vs. 20%). We observed a similar relationship for pain interference and fall risk (p < 0.001). Fewer than half of participants reported having been asked about falls in the past 12 months by their primary care physician (44%) or oncologist (36%).

Conclusion

Joint pain increases the risk of falls among women with breast cancer on adjuvant AI therapy. Health care providers should evaluate and manage arthralgia symptoms and implement fall-prevention strategies for those who are at increased risk.

Keywords

Breast cancer Aromatase inhibitors Fall risk Arthralgia Joint pain Falls 

Notes

Author contributions

Coby Basal, BA: conceptualization, data curation, investigation, methodology, writing—original draft, and writing—review and editing. Emily Vertosick, MPH: data curation, methodology, formal analysis, visualization, writing—original draft, and writing—review and editing. Theresa A. Gillis, MD: conceptualization, investigation, writing—original draft, and writing—review and editing. Qing Li, MS: conceptualization, data curation, formal analysis, methodology, writing—original draft, and writing—review and editing. Ting Bao, MD, DABMA, MS: conceptualization, investigation, writing—original draft, and writing—review and editing. Andrew Vickers, PhD: conceptualization, data curation, methodology formal analysis, investigation, visualization, writing—original draft, and writing—review and editing. Jun J. Mao, MD, MSCE: conceptualization, data curation, funding acquisition, investigation, methodology, writing—original draft, and writing—review and editing.

Funding

This work was supported in part by grants from the National Cancer Institute at the National Institutes of Health (grant numbers R01 CA158243, P30-CA008748) and by the Byrne Fund and the Translational Research and Integrative Medicine Fund, both at Memorial Sloan Kettering Cancer Center.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Research involving human participants and/or animals

The Institutional Review Board of the University of Pennsylvania approved the study protocol. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

References

  1. 1.
    Society AC. Breast Cancer Facts & Figures 2015-2016. Atlanta2015Google Scholar
  2. 2.
    Howell A (2005) Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62CrossRefPubMedGoogle Scholar
  3. 3.
    Coombes R, Kilburn L, Snowdon C, Paridaens R, Coleman RE, Jones SE, Jassem J, van de Velde C, Delozier T, Alvarez I, del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559–570CrossRefPubMedGoogle Scholar
  4. 4.
    Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877–3883CrossRefPubMedGoogle Scholar
  5. 5.
    Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU, ATAC Trialists’ Group (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9(9):866–872CrossRefPubMedGoogle Scholar
  6. 6.
    Jinks C, Jordan K, Croft P (2007) Osteoarthritis as a public health problem: the impact of developing knee pain on physical function in adults living in the community: (KNEST 3). Rheumatology 46(5):877–881CrossRefPubMedGoogle Scholar
  7. 7.
    Shumway-Cook A, Baldwin M, Polissar NL, Gruber W (1997) Predicting the probability for falls in community-dwelling older adults. Phys Ther 77(8):812–819CrossRefPubMedGoogle Scholar
  8. 8.
    Masud T, Morris RO (2001) Epidemiology of falls. Age Ageing 30:3–7CrossRefPubMedGoogle Scholar
  9. 9.
    Kitayuguchi J, Kamada M, Okada S, Kamioka H, Mutoh Y (2015) Association between musculoskeletal pain and trips or falls in rural Japanese community-dwelling older adults: a cross-sectional study. Geriatr Gerontol Int 15(1):54–64CrossRefPubMedGoogle Scholar
  10. 10.
    Leveille SG, Bean J, Bandeen-Roche K, Jones R, Hochberg M, Guralnik JM (2002) Musculoskeletal pain and risk for falls in older disabled women living in the community. J Am Geriatr Soc 50(4):671–678CrossRefPubMedGoogle Scholar
  11. 11.
    Leveille SG, Jones RN, Kiely DK, Hausdorff JM, Shmerling RH, Guralnik JM, Kiel DP, Lipsitz LA, Bean JF (2009) Chronic musculoskeletal pain and the occurrence of falls in an older population. JAMA 302(20):2214–2221CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Stone CA, Lawlor PG, Savva GM, Bennett K, Kenny RA (2012) Prospective study of falls and risk factors for falls in adults with advanced cancer. J Clin Oncol 30(17):2128–2133CrossRefPubMedGoogle Scholar
  13. 13.
    Walle NV, Kenis C, Heeren P et al (2014) Fall predictors in older cancer patients: a multicenter prospective study. BMC Geriatr 14(1):135CrossRefGoogle Scholar
  14. 14.
    Chen Z, Maricic M, Aragaki A et al (2009) Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the women’s health initiative. Osteoporos Int 20(4):527–536CrossRefPubMedGoogle Scholar
  15. 15.
    Spoelstra SL, Given BA, Schutte DL, Sikorskii A, You M, Given CW. Do older adults with cancer fall more often? A comparative analysis of falls in those with and without cancer. Paper presented at: Oncology nursing forum 2013Google Scholar
  16. 16.
    Rubenstein LZ (2006) Falls in older people: epidemiology, risk factors and strategies for prevention. Age Ageing 35(suppl_2):ii37–ii41CrossRefPubMedGoogle Scholar
  17. 17.
  18. 18.
    Mao JJ, Xie SX, Farrar JT, Stricker CT, Bowman MA, Bruner D, DeMichele A (2014) A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use. Eur J Cancer 50(2):267–276CrossRefPubMedGoogle Scholar
  19. 19.
    Mao JJ, Bruner DW, Stricker C, Farrar JT, Xie SX, Bowman MA, Pucci D, Xiaoyan Han, DeMichele A (2009) Feasibility trial of electroacupuncture for aromatase inhibitor—related arthralgia in breast cancer survivors. Integr Cancer Ther 8(2):123–129CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lamb SE, Jørstad-Stein EC, Hauer K, Becker C (2005) Development of a common outcome data set for fall injury prevention trials: the prevention of falls network Europe consensus. J Am Geriatr Soc 53(9):1618–1622CrossRefPubMedGoogle Scholar
  21. 21.
    Blyth FM, Cumming R, Mitchell P, Wang JJ (2007) Pain and falls in older people. Eur J Pain 11(5):564–571CrossRefPubMedGoogle Scholar
  22. 22.
    Stanmore EK, Oldham J, Skelton DA, O'Neill T, Pilling M, Campbell AJ, Todd C (2013) Fall incidence and outcomes of falls in a prospective study of adults with rheumatoid arthritis. Arthritis Care Res 65(5):737–744CrossRefGoogle Scholar
  23. 23.
    Sattar S, Alibhai SM, Spoelstra SL, Fazelzad R, Puts MT (2016) Falls in older adults with cancer: a systematic review of prevalence, injurious falls, and impact on cancer treatment. Support Care Cancer 24(10):4459–4469CrossRefPubMedGoogle Scholar
  24. 24.
    Wildes TM, Dua P, Fowler SA, Miller JP, Carpenter CR, Avidan MS, Stark S (2015) Systematic review of falls in older adults with cancer. J Geriatr Oncol 6(1):70–83CrossRefPubMedGoogle Scholar
  25. 25.
    Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ (2016) Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 159(2):327–333CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Patel KV, Phelan EA, Leveille SG, Lamb SE, Missikpode C, Wallace RB, Guralnik JM, Turk DC (2014) High prevalence of falls, fear of falling, and impaired balance in older adults with pain in the United States: findings from the 2011 National Health and Aging Trends Study. J Am Geriatr Soc 62(10):1844–1852CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Choksi P, Williams M, Kidwel K, Stella J, Soyster M (2016) Adjuvant aromatase inhibitors in early breast cancer may not increase the risk of falls. J Bone Rep Recomm 2(2)Google Scholar
  28. 28.
    Winters-Stone KM, Torgrimson B, Horak F, Eisner A, Nail L, Leo MC, Chui S, Luoh SW (2011) Identifying factors associated with falls in postmenopausal breast cancer survivors: a multi-disciplinary approach. Arch Phys Med Rehabil 92(4):646–652CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Guerard EJ, Deal AM, Williams GR, Jolly TA, Nyrop KA, Muss HB (2015) Falls in older adults with cancer: evaluation by oncology providers. J Oncol Pract 11(6):470–474CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Murphy SL, Williams CS, Gill TM (2002) Characteristics associated with fear of falling and activity restriction in community-living older persons. J Am Geriatr Soc 50(3):516–520CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Davis JC, Robertson MC, Ashe MC, Liu-Ambrose T, Khan KM, Marra CA (2010) International comparison of cost of falls in older adults living in the community: a systematic review. Osteoporos Int 21(8):1295–1306CrossRefPubMedGoogle Scholar
  32. 32.
    Munch T, Harrison SL, Barrett-Connor E et al. Pain and falls and fractures in community-dwelling older men. Age Ageing. 2015;afv125Google Scholar
  33. 33.
    Stubbs B, Binnekade T, Eggermont L, Sepehry AA, Patchay S, Schofield P (2014) Pain and the risk for falls in community-dwelling older adults: systematic review and meta-analysis. Arch Phys Med Rehabil 95(1):175–187. e179CrossRefPubMedGoogle Scholar
  34. 34.
    Robarge JD, Duarte DB, Shariati B, Wang R, Flockhart DA, Vasko MR (2016) Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons. Exp Neurol 281:53–65CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Borrie AE, Kim RB. Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers. Expert Opin Drug Metab Toxicol. 2016;1–8Google Scholar
  36. 36.
    Din OS, Dodwell D, Wakefield RJ, Coleman RE (2010) Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat 120(3):525–538CrossRefPubMedGoogle Scholar
  37. 37.
    Brown JC, Mao JJ, Stricker C, Hwang WT, Tan KS, Schmitz KH (2014) Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors. Breast J 20(1):22–28CrossRefPubMedGoogle Scholar
  38. 38.
    Ganz DA, Higashi T, Rubenstein LZ (2005) Monitoring falls in cohort studies of community-dwelling older people: effect of the recall interval. J Am Geriatr Soc 53(12):2190–2194CrossRefPubMedGoogle Scholar
  39. 39.
    Sanders KM, Stuart AL, Scott D, Kotowicz MA, Nicholson GC (2015) Validity of 12-month falls recall in community-dwelling older women participating in a clinical trial. Int J Endocrinol 2015:1–6CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.MedicineMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Epidemiology and BiostatisticsMemorial Sloan Kettering Cancer CenterNew YorkUSA
  3. 3.NeurologyMemorial Sloan Kettering Cancer CenterNew YorkUSA
  4. 4.Bendheim Integrative Medicine CenterNew YorkUSA

Personalised recommendations